Why the Market Re-Rated This Uranium Update
Despite broader market volatility, Paladin delivered a strong operational result, with the share price rising around 10% following the quarterly update. In our view, the move reflects improving execution and growing confidence in the company’s production profile.
During the quarter, Paladin produced 1.23 million pounds of uranium and sold…
Tech Stocks
Test text
Funding in Place for the Next Phase of US Expansion
Metallium has completed a A$75 million capital raising at A$0.84 per share, led by US-based institutional investors. The placement resulted in the issuance of approximately 89 million new shares and provides the company with the balance sheet strength needed to accelerate its next phase of…
Weebit Nano looks extremely promising
Weebit Nano (ASX: WBT) has had a remarkable run, with shares climbing more than 50 per cent over the past 12 months to trade around A$5.44. The company develops next-generation memory technology called ReRAM and has built serious momentum after signing licensing deals with two of the world's biggest chipmakers.…
Hub24 posts record inflows, but valuation looks stretched
Hub24 (ASX: HUB) jumped 8 per cent on Tuesday after smashing quarterly records once again. The wealth platform pulled in A$5.6 billion in net inflows for the December quarter, pushing first-half inflows to a record A$10.7 billion. Total funds under administration now sit at A$152.3 billion, up…
ARR Grew, Sentiment Fell
Qoria (ASX: QOR) delivered what we would describe as a reasonably solid quarterly result, yet the market reaction told a very different story. The share price fell around 25% on the day, which tells us expectations were clearly set higher. In this note, we want to unpack what actually happened in…
Funding the Next Chapter of Growth, Not Plugging Holes
Nanoveu (ASX:NVU) has raised A$7.5 million through an upsized strategic placement to new and existing institutional investors at A$0.088 per share. From an investor perspective, this capital raise is best viewed as funding for the company’s next phase of execution rather than a balance sheet repair.
Importantly,…
The China Regulatory Path Is Still Moving Forward
Telix Pharmaceuticals (ASX:TLX) has had a challenging start to the year, with the share price down around 55% and now trading near A$11.70 at the time of writing. In our experience, this is often when a stock becomes worth revisiting. Sustained share price weakness can create opportunities,…
The Cost of Optimistic Timelines in Battery Manufacturing
Novonix has experienced a volatile year, with the share price ranging from highs near A$1.00 to more recent levels around A$0.42. That decline reflects a series of setbacks that have weighed on investor confidence in Novonix and reshaped the near term growth narrative.
Around November, the company lost…
What Retail Investors Need to Know Before Chasing the Story
4DMedical has quickly become one of the more talked about stocks in the market, and with that attention comes the need for clarity.
In this piece, we want to break down the company’s latest investor presentation and what it really means for shareholders. That includes a…
Why TSMC 77% of Revenue Now Comes From the Cutting Edge
TSMC, the founding force behind the global foundry model and the manufacturer of the world’s most advanced semiconductor chips, delivered another very strong quarter.
Revenue reached approximately US$33 billion, representing 25% year-on-year growth. This result reinforces a trend we continue to see across the semiconductor…
